BURLINGTON, Mass., March 08, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at 29th Annual ROTH Conference on Tuesday, March 14, 2017 at the Ritz-Carlton, Laguna Niguel, CA.
The Company is scheduled to present at 9:00 a.m. PDT.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: LeMaitre Vascular, Inc. Investor Relations Steven Chehames +1-781-425-1659 [email protected]


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



